Population-based randomized trial of screening for clinically significant prostate cancer ProScreen: pilot study.

To evaluate feasibility of a population-based screening trial using prostate-specific antigen (PSA), a kallikrein panel and multiparametric magnetic resonance imaging (MRI) aimed at minimising overdiagnosis, while retaining mortality benefit.